H.R. 3264: American Life Sciences Competitiveness Act of 2007
Before you vote › Federal bills
H.R. 3264: American Life Sciences Competitiveness Act of 2007
110th Congress · introduced 2007-07-31 · Taxation · Latest: Sponsor introductory remarks on measure. (CR E1689-1690)
federal
Follow this bill, step by step
- Where it came from: introduced 2007-07-31 · official record
- Who proposed it: Rep. Schwartz, Allyson Y. [D-PA-13] · what a sponsor is
- What happened next: no floor votes in our records yet. Why?
- Where it stands now: Sponsor introductory remarks on measure. (CR E1689-1690) Not final yet: this can still change. We check for updates every day.
- If it becomes law and spends money: follow the money to money laws, then agencies and contracts and grants.
Official title
American Life Sciences Competitiveness Act of 2007
Plain summary
American Life Sciences Competitiveness Act of 2007 - Amends the Internal Revenue Code to allow biomedical research corporations to: (1) engage in investment activity involving shifts in ownership without incurring limitations on net operating loss carryforwards; (2) claim a full research and development tax credit for contract research expenses (currently, limited to 65%); (3) claim a business tax credit for 20% of eligible countermeasures research expenses (for biomedical threats); and (4) claim a tax-free rollover of gain from stock sales reinvested in another biomedical research corporation. Expands the tax credit for clinical testing expenses for drugs to treat rare diseases (orphan drugs) to include expenses incurred after an application is made to the Food and Drug Administration (FDA) but before receipt of an orphan drug designation. Allows individual taxpayers a 20% tax credit for equity investments in small biomedical research firms engaged in incubational research (i.e., research conducted prior to large-scale clinical trials).
Congressional Research Service summary (Introduced in House), quoted unchanged (nonpartisan). Read the source.
What a vote does
A “Yea” vote
If it passes both chambers and is signed, it becomes law.
A “Nay” vote
If it is not passed, current law stays as it is.
PSI Sci description of the legislative step (not an opinion).
What does this mean? (plain words)
Official text
American Life Sciences Competitiveness Act of 2007
Source: Congressional Research Service summary (Introduced in House)
AI explanation – may be wrong, check the official text
No AI explanation yet. It takes up to a minute to write and is then saved for everyone.
Limited to a few requests an hour per person.
The strongest published arguments
Arguments for (supporters)
Needs sources: no published arguments on this side yet. We only show items backed by a published source. Suggest one.
Arguments against (opponents)
Needs sources: no published arguments on this side yet. We only show items backed by a published source. Suggest one.
Alternatives
Needs sources: no published alternatives yet (for example a different bill, a law instead of an amendment, or keeping current law). We only show items backed by a published source. Suggest one.
How did my representative vote? · This bill's floor votes
Officials and money
Sponsor: Rep. Schwartz, Allyson Y. [D-PA-13] · 3 cosponsors
Cost estimate: No cost estimate published yet.
Cosponsors on this site
Richard E. Neal (D-MA)
No linked floor roll calls in our collected records yet. This does not mean the bill has never had a vote. Check the official bill history.
Sources
- Congressional Research Service summary (Introduced in House)
- Congress.gov
- Data: GovInfo BILLSTATUS bulk data (Library of Congress), BILLSTATUS-110hr3264.xml <https://www.govinfo.gov/bulkdata/BILLSTATUS/110/hr>
Record fed-us-cong110-hr3264 · catalog fed-us-congress-bills-cong110 · updated 2026-11-15 by psicol fed-bills-cong110